• • Physicians ordering transfusion must have current knowledge of the risks of (see appendix 1) and alternatives to (see appendix 2) red blood cell and plasma transfusion. • • Patients may benefit from comparison of risks associated with daily life (see appendix 3).
• • Risk estimations are updated frequently. Websites useful for transfusion and risk information include:
- The attending physician should explain to the patient the reason for transfusion, obtain informed consent and document the discussion in the patient's record.
Red Blood Cells
• • Red blood cell transfusion is one of several alternatives or adjunctive therapies for patients with clinically significant anemia, or anticipated anemia with scheduled surgery. Suitable alternatives must be considered whenever time is available for their implementation. • • In acute blood loss, transfusion should not be used to expand vascular volume when oxygen carrying capacity is adequate. • • In chronic anemia, physiologic adaptation may be sufficient to allow time for use of transfusion alternatives.
• • Red blood cell transfusion should not be dictated by a single hemoglobin trigger, but should be based on complete evaluation of the patient including volume status, tissue perfusion and comorbid disease.
-Red blood cell transfusion is recommended to prevent or alleviate symptoms, signs or morbidity due to inadequate tissue oxygen delivery caused by anemia. -Red blood cell transfusion is rarely indicated when the hemoglobin concentration is >100 g/L and is almost always indicated when it is < 60 g/L. -A Canadian randomised controlled trial in critically ill adult patients showed that a transfusion threshold hemglobin level of 70 g/L (average achieved 85 g/L) was associated with less red blood cell transfusion, but similar morbidity and mortality to a transfusion threshold of 100 g/L (average achieved 107 g/L). 2 The applicability of the results of this trial to patients with cardiac disease is uncertain.
• • There are no well-defined criteria for red blood cell transfusion in children, and clinical assessment of tissue perfusion is required. 
Autologous Blood
Autologous blood transfusion avoids the very low risks of transmission of undetected infectious agents that is associated with allogeneic transfusion. Risks of hemolytic reaction (wrong unit) and bacterial sepsis (contamination) are the same for autologous and allogeneic blood. Based on comorbid conditions in an individual patient, the risk of collection and transfusion of autologous blood may be more or less than the risk of transfusion of allogeneic blood. Predonation of autologous blood is a therapeutic option for appropriate patients undergoing elective surgery if the likelihood of transfusion is high. Patients may choose to accept criteria for transfusion of autologous blood which differ from those for transfusion of allogeneic blood. In order to optimize use of autologous collection and transfusion and minimize iatrogenic anemia, risk and transfusion criteria for autologous blood must be discussed with patients before autologous collection is performed.
Plasma Transfusion
Plasma transfusion is recommended where there is clinically significant bleeding in patients with liver disease and increased PT, INR or aPTT. Plasma transfusion is recommended in patients with acute disseminated intravascular coagulation (DIC) with active bleeding associated with increased PT, INR or aPTT. The condition triggering the DIC must also be treated. Plasma should be administered in the context of massive transfusion (usually > 1 patient blood volume in 24 hours) if there is microvascular bleeding associated with a significantly increased PT, INR or aPTT.
-If PT, INR or aPTT cannot be measured quickly, plasma may be transfused in an attempt to stop diffuse nonsurgical bleeding. Plasma should be used in the treatment of thrombotic thrombocytopenic purpura or adult hemolytic uremic syndrome.
-Plasma transfusion or exchange is not recommended in the classic form of pediatric hemolytic uremic syndrome.
Single Coagulation Deficiency
Plasma should be used in patients with acquired deficiencies of a single coagulation factor only when DDAVP or appropriate recombinant factors or factor concentrates are ineffective or unavailable.
-Plasma should be used in these patients only when bleeding has occurred or is reasonably expected to occur from surgery or other invasive procedures.
Multiple Coagulation Deficiency Practice Point
Plasma transfusion should not be used to correct warfarin effect when time is available to allow for spontaneous or vitamin K-induced normalization of PT or INR During warfarin therapy, small doses (1-2 mg) of vitamin K may be effective to normalize PT or INR, without producing prolonged warfarin insensitivity (sc or im administration preferred to iv). Plasma transfusion should be considered in patients with severe vitamin K deficiency or warfarin excess who are preparing for emergency surgical or invasive procedures. Plasma may be administered to prepare for surgery or invasive procedures when the results of PT, INR, aPTT or other coagulation assays are abnormal. Plasma is not indicated for percutaneous liver biopsy, thoracentesis or paracentesis in patients with liver disease and INR of 2.0 or less. 
